ArticleThe Journal of general virology2026
Structural basis of porcine reproductive and respiratory syndrome virus 2 neutralization by a GP4-targeting monoclonal antibody.
Article in The Journal of general virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is a genetically diverse RNA virus that causes reproductive failure and respiratory disease in pigs, leading to major economic losses worldwide. Although inactivated and live-attenuated vaccines are available, they provide only partial protection, allowing endemic circulation, persistent transmission and recurrent outbreaks. The limited efficacy of current vaccines reflects the incomplete understanding of immune correlates of protection. Here, we describe a murine monoclonal antibody (IgG #18) with potent, strain-specific neutralizing activity against PRRSV-2. Epitope mapping localized its binding site to the N-terminal region of the minor glycoprotein GP4. Functional and biochemical analyses demonstrated high-affinity binding and effective neutralization, while crystallographic studies revealed its atomic structure in complex with an epitope peptide. To our knowledge, this structure provides the first structural snapshot of a neutralization epitope within the PRRSV glycoproteins, providing insights into the conformation of this key component of the PRRSV envelope complex. This structure also explains the restricted specificity of IgG #18, highlighting the challenge of epitope variability across PRRSV species. Our findings advance understanding of antibody-mediated neutralization and provide an initial framework for the use of structural information in the design of next-generation immunogens aimed at eliciting protective responses against genetically diverse PRRSV strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.